EBUS-TBNA联合[18F]FDG-PET/CT对III期NSCLC放化疗靶区定义的影响
该研究分析了180例III期NSCLC患者,评估EBUS-TBNA在PET/CT基础上对纵隔淋巴结分期及临床靶区的影响。结果显示PET/CT假发现率随淋巴结站距离增加而升高,EBUS-TBNA使22.2%患者的靶区发生改变。结论推荐EBUS-TBNA作为III期NSCLC放化疗分期的重要组成部分。
要点
- PET/CT假发现率从第一梯队5.3%升至第三梯队69.1%。
- EBUS-TBNA使22.2%患者靶区改变,其中6.7%扩大、15.5%缩小。
- 推荐EBUS-TBNA作为III期NSCLC放化疗分期的组成部分。
核心结论
- PET/CT假发现率随淋巴结与原发肿瘤距离增加而显著升高,EBUS-TBNA联合PET/CT可提高靶区定义准确性,尤其对第三梯队淋巴结。
研究设计与样本
- 回顾性分析2011年12月至2018年6月连续180例接受PET/CT和EBUS-TBNA的III期NSCLC患者,由专家放射科医生和核医学医生评估淋巴结站,两名独立放射肿瘤学家评估CTV。
主要发现
- EBUS-TBNA取样675个淋巴结站,其中291个肿瘤细胞阳性,总阳性率43%。
- EBUS阳性率从第一梯队85.8%降至第二梯队42.4%和第三梯队9.6%(p<0.0001)。
- PET/CT假发现率从第一梯队5.3%升至第二梯队32.9%和第三梯队69.1%(p<0.0001)。
- FDG-PET/CT在不同梯队的敏感性为85%至99%,特异性为67%至80%。
- 22.2%患者因EBUS-TBNA结果改变CTV,其中6.7%扩大、15.5%缩小。
关键数值与推荐
- 淋巴结按淋巴链距离分组:第一梯队为同侧肺门,第二梯队为第7站和同侧第4站,第三梯队为其余纵隔和对侧肺门。
临床怎么用
- 在III期NSCLC放化疗前,应将EBUS-TBNA作为分期组成部分,尤其需系统评估第三梯队淋巴结以修正PET/CT假阳性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: PURPOSE/INTRODUCTION: [18F]FDG-PET/CT is the standard imaging-technique for radiation treatment (RT) planning in locally advanced non-small cell lung cancer (NSCLC). The purpose of this study was to examine the additional value of endobronchial-ultrasound transbronchial needle aspiration (EBUS-TBNA) to standard PET/CT for mediastinal lymph-node (LN) staging and its impact on clinical target volume (CTV). MATERIALS AND METHODS: All consecutive patients with primary stage III NSCLC who underwent [18F]FDG-PET/CT and EBUS-TBNA prior to RT were analyzed from 12/2011 to 06/2018. LN-stations were assessed by an expert-radiologist and a nuclear medicine-physician. CTV was evaluated by two independent radiation oncologists. LNs were grouped with increasing distance along the lymphatic chains from primary tumor into echelon-1 (ipsilateral hilum), echelon-2 (LN-station 7 and ipsilateral 4), and echelon-3 (remaining mediastinum and contralateral hilum). RESULTS: A total of 675 LN-stations of which 291 were positive for tumor-cells, were sampled by EBUS-TBNA in 180 patients. The rate of EBUS-positive LNs was 43% among all sampled LNs. EBUS-positivity in EBUS-probed LNs decreased from 85.8% in echelon-1 LNs to 42.4%/ 9.6% in echelon-2/ -3 LNs, respectively (p < 0.0001, Fisher's exact test). The false discovery rate of PET in comparison with EBUS results rose from 5.3% in echelon-1 to 32.9%/ 69.1% in echelon-2/ -3 LNs, respectively (p < 0.0001, Fisher's exact test). Sensitivity and specificity of FDG-PET/CT ranged from 85 to 99% and 67 to 80% for the different echelons. In 22.2% patients, EBUS-TBNA finding triggered changes of the treated CTV, compared with contouring algorithms based on FDG-avidity as the sole criterion for inclusion. CTV was enlarged in 6.7% patients due to EBUS-positivity in PET-negative LN-station and reduced in 15.5% by exclusion of an EBUS-negative but PET-positive LN-station. CONCLUSION: The false discovery rate of [18F]FDG-PET/CT increased markedly with distance from the primary tumor. Inclusion of systematic mediastinal LN mapping by EBUS-TBNA in addition to PET/CT has the potential to increase accuracy of target volume definition, particularly in echelon-3 LNs. EBUS-TBNA is recommended as integral part of staging for radiochemotherapy in stage III NSCLC.
引用
- Guberina M, Darwiche K, Hautzel H, et al. Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC. Eur J Nucl Med Mol Imaging. 2021. PMID: 33547554. doi:10.1007/s00259-021-05204-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。